These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26927534)

  • 1. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia.
    Montejo ÁL; Arango C; Bernardo M; Carrasco JL; Crespo-Facorro B; Cruz JJ; Del Pino J; García Escudero MA; García Rizo C; González-Pinto A; Hernández AI; Martín Carrasco M; Mayoral Cleries F; Mayoral van Son J; Mories MT; Pachiarotti I; Ros S; Vieta E
    Rev Psiquiatr Salud Ment; 2016; 9(3):158-73. PubMed ID: 26927534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
    Hummer M; Huber J
    Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management.
    Holt RI; Peveler RC
    Clin Endocrinol (Oxf); 2011 Feb; 74(2):141-7. PubMed ID: 20455888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
    O'Keane V
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy].
    Riecher-Rössler A; Schmid C; Bleuer S; Birkhäuser M
    Neuropsychiatr; 2009; 23(2):71-83. PubMed ID: 19573500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperprolactinaemia and bone mineral density].
    Kostrzak A; Męczekalski B
    Pol Merkur Lekarski; 2015 Aug; 39(230):122-5. PubMed ID: 26319389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic-induced hyperprolactinaemia.
    Inder WJ; Castle D
    Aust N Z J Psychiatry; 2011 Oct; 45(10):830-7. PubMed ID: 21714721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
    Cookson J; Hodgson R; Wildgust HJ
    J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the association between antipsychotic use and hyperprolactinaemia.
    Bushe C; Shaw M; Peveler RC
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):46-55. PubMed ID: 18477620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of hyperprolactinaemia on sexual function in patients with psychosis.
    Smith SM
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):63-9. PubMed ID: 18477622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.
    Wieck A; Haddad PM
    Br J Psychiatry; 2003 Mar; 182():199-204. PubMed ID: 12611781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
    Haddad PM; Hellewell JS; Wieck A
    J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced hyperprolactinaemia: case studies and review.
    Mittal S; Prasad S; Ghosh A
    Postgrad Med J; 2018 Apr; 94(1110):226-229. PubMed ID: 29122927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of hyperprolactinaemia as an entity in psychiatric patients.
    Kohen D; Wildgust HJ
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):6-11. PubMed ID: 18477616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin awareness: an essential consideration for physical health in schizophrenia.
    Montejo AL
    Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotics and hyperprolactinaemia: clinical recommendations.
    Peveler RC; Branford D; Citrome L; Fitzgerald P; Harvey PW; Holt RI; Howard L; Kohen D; Jones I; O'Keane V; Pariente CM; Pendlebury J; Smith SM; Yeomans D
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):98-103. PubMed ID: 18477626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.